Medical Oncology Unit, Hospital Vito Fazzi, Lecce 73100, Italy.
Int J Mol Sci. 2013 Sep 30;14(10):19731-62. doi: 10.3390/ijms141019731.
Pancreatic adenocarcinoma displays a variety of molecular changes that evolve exponentially with time and lead cancer cells not only to survive, but also to invade the surrounding tissues and metastasise to distant sites. These changes include: genetic alterations in oncogenes and cancer suppressor genes; changes in the cell cycle and pathways leading to apoptosis; and also changes in epithelial to mesenchymal transition. The most common alterations involve the epidermal growth factor receptor (EGFR) gene, the HER2 gene, and the K-ras gene. In particular, the loss of function of tumor-suppressor genes has been documented in this tumor, especially in CDKN2a, p53, DPC4 and BRCA2 genes. However, other molecular events involved in pancreatic adenocarcinoma pathogenesis contribute to its development and maintenance, specifically epigenetic events. In fact, key tumor suppressors that are well established to play a role in pancreatic adenocarcinoma may be altered through hypermethylation, and oncogenes can be upregulated secondary to permissive histone modifications. Indeed, factors involved in tumor invasiveness can be aberrantly expressed through dysregulated microRNAs. This review summarizes current knowledge of pancreatic carcinogenesis from its initiation within a normal cell until the time that it has disseminated to distant organs. In this scenario, highlighting these molecular alterations could provide new clinical tools for early diagnosis and new effective therapies for this malignancy.
胰腺导管腺癌表现出多种分子变化,这些变化随时间呈指数级进化,不仅使癌细胞能够存活,还能侵袭周围组织并转移到远处。这些变化包括:癌基因和肿瘤抑制基因的遗传改变;细胞周期和导致细胞凋亡的途径的改变;以及上皮细胞到间充质转化的改变。最常见的改变涉及表皮生长因子受体(EGFR)基因、HER2 基因和 K-ras 基因。特别是,在这种肿瘤中已经记录到肿瘤抑制基因的功能丧失,特别是在 CDKN2a、p53、DPC4 和 BRCA2 基因中。然而,其他参与胰腺腺癌发病机制的分子事件也有助于其发展和维持,特别是表观遗传事件。事实上,已经确定在胰腺腺癌中发挥作用的关键肿瘤抑制因子可能通过 hypermethylation 发生改变,而癌基因可能由于允许组蛋白修饰而被上调。实际上,通过失调的 microRNAs 可以异常表达参与肿瘤侵袭性的因子。这篇综述总结了从正常细胞内起始到扩散到远处器官的胰腺发生癌变的最新知识。在这种情况下,强调这些分子改变可以为早期诊断提供新的临床工具,并为这种恶性肿瘤提供新的有效治疗方法。